XTL Biopharmaceuticals Ltd. (XTLB) and Motif Bio plc (NASDAQ:MTFB) Comparing side by side

We are comparing XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) and Motif Bio plc (NASDAQ:MTFB) on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XTL Biopharmaceuticals Ltd. N/A 0.00 2.99M 0.38 5.97
Motif Bio plc N/A 0.00 22.87M -2.02 0.00

Demonstrates XTL Biopharmaceuticals Ltd. and Motif Bio plc earnings per share (EPS), top-line revenue and valuation.


Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
XTL Biopharmaceuticals Ltd. 0.00% 33.2% 28.8%
Motif Bio plc 0.00% 0% 0%

Institutional and Insider Ownership

The shares of both XTL Biopharmaceuticals Ltd. and Motif Bio plc are owned by institutional investors at 11.6% and 7.46% respectively. 1% are XTL Biopharmaceuticals Ltd.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XTL Biopharmaceuticals Ltd. -9.64% -8.16% -0.44% 30.06% -8.16% 30.06%
Motif Bio plc 3.83% -81.17% -75.8% -76.6% -78.75% -71.17%

For the past year XTL Biopharmaceuticals Ltd. had bullish trend while Motif Bio plc had bearish trend.


XTL Biopharmaceuticals Ltd. beats on 7 of the 7 factors Motif Bio plc.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and SjogrenÂ’s syndrome. The company also develops recombinant human erythropoietin for the treatment of multiple myeloma patients. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.